Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 3, 2017, Pages 528-532

  Dillman, Robert O ^a,b,c  

^a AiVita Biomedical   (United States)

^b Hoag Family Cancer Institute   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer stem cells; dendritic cells; patient specific neoantigens; therapeutic vaccines; tumor associated antigens

Indexed keywords

CANCER VACCINE; CHECKPOINT KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; TALIMOGENE LAHERPAREPVEC; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; META ANALYSIS (TOPIC); METASTATIC MELANOMA; NONHUMAN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR ASSOCIATED LEUKOCYTE; DRUG DEVELOPMENT; NEOPLASMS; TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DRUG DISCOVERY; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 85006868197     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1244149     Document Type: Note

References (37)

1. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32; PMID:18716299; http://dx.doi.org/10.1056/NEJMsa0707052
2. Lu T, Seto WK, Zhu RX, Lai CL, Uyen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B ad C infection. World J Gastroenterol 2013; 19(47):8887-94; PMID:24379612; http://dx.doi.org/10.3748/wjg.v19.i47.8887
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5):411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294
4. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33(25)2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
5. Dillman RO. Melanoma Vaccines:Trials and Tribulations. Vaccine Dev Ther 2013; 3:57-78; http://dx.doi.org/10.2147/VDT.S32396
6. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, et al. Active idiotypic vaccination vs. control immunotherapy for follicular lymphoma. J Clin Oncol 2014; 32:1797-803; PMID:24799467; http://dx.doi.org/10.1200/JCO.2012.43.9273
7. Lawson DH, Lee S, Zhao F, Tarhini AA, Margolin KA, Ernstoff MS, Atkins MB, Cohen GI, Whiteside TL, Butterfield LH, et al. Randomized, placebo-controlled, phase III trial yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma:a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol 2015; 33(34)4066-76; PMID:26351350; http://dx.doi.org/10.1200/JCO.2015.62.0500
8. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3 positive non-small-cell lung cancer (MAGRIT):a randomized, double-blind placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17(6):822-35; PMID:27132212; http://dx.doi.org/10.1016/S1470-2045(16)00099-1
9. Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, Schneebaum S, Schuchter L, Gammon G. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25:474s; http://dx.doi.org/10.1016/j.clon.2013.04.009
10. Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 2015; 51(16):2321-9; PMID:26283035; http://dx.doi.org/10.1016/j.ejca.2015.07.035
11. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, et al. Active specific immunotherapy for stage II and stage III human colon cancer:a randomized trial. Lancet 1999; 353(9150):345-50; PMID:9950438; http://dx.doi.org/10.1016/S0140-6736(98)07186-4
12. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, Parmiani G, Tosti G, Kirkwood JM, Hoos A, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma:the C-100-21 Study Group. J Clin Oncol 2008; 26(6):955-62; PMID:18281670; http://dx.doi.org/10.1200/JCO.2007.11.9941
13. Dillman RO, DeLeon C, Beutel LD, Barth NM, Schwartzberg LS, Spitler LE, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer:induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002; 17(1):51-66; PMID:11915174; http://dx.doi.org/10.1089/10849780252824073
14. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348(6230):69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8):711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
16. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372(26):2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
17. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32(10):1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
18. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373(19):1803-13; PMID:26406148; http://dx.doi.org/10.1056/NEJMoa1510665
19. Brahmer J, Reckamp KL, Baas P, Crin∫ L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab vs docetaxel in advanced squamous-cell non-small-cell-lung cancer. N Engl J Med 2015; 373(2)123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
20. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab vs docetaxel in advanced nonsquamous non-small-cell-lung cancer. N Engl J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
21. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-cell lung cancer (KEYNOTE-010):a randomized controlled trial. Lancet 2016; 387(10027):1540-50; PMID:26712084; http://dx.doi.org/10.1016/S0140-6736(15)01281-7
22. Sidaway P. Bladder cancer:atezolizumab effective against advanced-stage disease. Nat Rev Urol 2016; 13(5)238; PMID:27001012; http://dx.doi.org/10.1038/nrurol.2016.60
23. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372(4):311-9; PMID:25482239; http://dx.doi.org/10.1056/NEJMoa1411087
24. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33(34):4015-22; PMID:26351349; http://dx.doi.org/10.1200/JCO.2015.62.3397
25. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012):an open-label, multicenter, phase Ib trial. Lancet Oncol 2016; 17(7):956-65; PMID:27247226; http://dx.doi.org/10.1016/S1470-2045(16)30066-3
26. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, et al. PD-1 blockade with pembrolizumab in advanced Merkel-Cell carcinoma. N Engl J Med 2016; 374(26):2542; PMID:27093365; http://dx.doi.org/10.1056/NEJMoa1603702
27. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373(1):23034; http://dx.doi.org/10.1056/NEJMoa1504030
28. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012; 72(13)3125-30; PMID:22721837; http://dx.doi.org/10.1158/0008-5472.CAN-11-4094
29. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Jundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348(6236):803-8; PMID:25837513; http://dx.doi.org/10.1126/science.aaa3828
30. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008; 20:286-95; PMID:18951039; http://dx.doi.org/10.1016/j.smim.2008.09.006
31. Dillman RO, Nistor GI, Cornforth AN. Dendritic cell vaccines for melanoma:past, present, and future. Melanoma Manage 2016 [in press].
32. Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy:a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012; 3(8):641-9; http://dx.doi.org/10.1097/CJI.0b013e31826f79c8
33. th Annual Meeting of the American Association for Cancer Research, New Orleans, LA. FifteenApril2016. Proc Am Assoc Cancer Res (#7827)
34. Dillman RO, McClay EF, Barth NM, Amatruda TT, Schwartzberg LS, Mahdavi K, de Leon C, Ellis RE, DePriest C. Dendritic cell versus tumor cell presentation of autologous antigens for patient-specific, active specific immunotherapy:impact on long-term survival in metastatic melanoma patients with either no evidence of disease or detectable metastases at the time of treatment. Cancer Biother Radiopharm 2015; 30(5):187-94; PMID:26083950; http://dx.doi.org/10.1089/cbr.2015.1843
35. Oldham RK. Biotherapy:the fourth modality of cancer treatment. J Cell Physiol Suppl 1986; 4:91-9; PMID:2427531; http://dx.doi.org/10.1002/jcp.1041290416
36. Dillman RO. Cancer Immunotherapy. Cancer Biother Radiopharm 2011; 26(1):1-64; PMID:21355777; http://dx.doi.org/10.1089/cbr.2010.0902
37. Dillman RO, Cornforth AN, Nistor GI. Cancer stem cell antigen-based vaccines:the preferred strategy for active specific immunotherapy of metastatic melanoma? Expert Opin Biol Ther 2013; 13(5):643-56; PMID:23451922; http://dx.doi.org/10.1517/14712598.2013.759556